Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Docetaxel
Drug ID BADD_D00699
Description Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel reversibly binds to tubulin with high affinity in a 1:1 stoichiometric ratio
Indications and Usage For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
Marketing Status approved; investigational
ATC Code L01CD02
DrugBank ID DB01248
KEGG ID D02165; D07866
MeSH ID D000077143
PubChem ID 148124
TTD Drug ID D0O5WP
NDC Product Code 0955-1020; 43066-001; 43598-259; 0409-0367; 70121-1222; 70700-175; 68554-0075; 43598-389; 45963-765; 72485-216; 17359-9100; 43598-610; 43598-611; 47335-895; 55150-378; 57884-3041; 57884-3042; 68083-399; 68083-400; 57884-3043; 70121-1221; 72485-214; 54893-0008; 65129-1298; 16729-267; 55150-380; 62332-678; 0143-9205; 43066-006; 68083-401; 0409-4235; 70121-1223; 43066-010; 55150-379; 66758-950; 0409-0368; 70700-174; 46708-678; 47335-323; 67457-781; 0409-0366; 65129-1141; 45963-734; 0409-0365; 70700-176; 0955-1021; 65129-1189; 66758-050; 0409-5068; 72485-215; 0955-1022; 0143-9204; 43598-258; 47335-939
UNII 15H5577CQD
Synonyms Docetaxel | Docetaxel Trihydrate | Docetaxol | Docetaxel Hydrate | Taxoltere Metro | RP 56976 | RP-56976 | RP56976 | Taxotere | Docetaxel Anhydrous | N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol | N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol | NSC 628503
Chemical Information
Molecular Formula C43H53NO14
CAS Registry Number 114977-28-5
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O) O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood alkaline phosphatase increased13.04.02.004--
Liver function test normal13.03.04.032---
Hot flush08.01.03.027; 21.02.02.001; 24.03.01.005--
Recall phenomenon12.02.06.001; 23.03.07.005--
Adverse event08.06.01.010---
Breast disorder21.05.04.004---
Cardiac disorder02.11.01.003---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Embolism24.01.01.009--
Infestation11.09.01.001; 23.11.01.002---
Inflammation08.01.05.007; 10.02.01.089---
Malnutrition14.03.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
Metastatic neoplasm16.16.01.007---
Neoplasm progression16.16.02.005---
Decreased appetite08.01.09.028; 14.03.01.005--
Feeling of body temperature change08.01.09.012---
Inner ear disorder04.04.02.002---
Lacrimal disorder06.08.02.005---
Polyp08.01.06.010; 16.02.02.005---
Blood disorder01.05.01.004---
Disease progression08.01.03.038--
Drug intolerance08.06.01.013---
Hepatobiliary disease09.01.08.003---
Renal impairment20.01.03.010---
Non-cardiac chest pain08.01.08.006; 22.12.02.009--
Neutropenic colitis01.02.03.010; 07.08.01.014---
Effusion08.01.03.052---
Exfoliative rash23.03.07.006---
The 10th Page    First    Pre   10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene